Valneva SE (0OB3.L)
EUR 1.82
(2.0%)
EUR 1.82
(2.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 341.14 Million EUR | -15.04% |
| 2022 | 401.54 Million EUR | -37.92% |
| 2021 | 646.77 Million EUR | 73.98% |
| 2020 | 371.74 Million EUR | 186.9% |
| 2019 | 129.57 Million EUR | 49.41% |
| 2018 | 86.72 Million EUR | -10.3% |
| 2017 | 96.67 Million EUR | -9.51% |
| 2016 | 106.83 Million EUR | -18.36% |
| 2015 | 130.85 Million EUR | 26.95% |
| 2014 | 103.07 Million EUR | -6.54% |
| 2013 | 110.28 Million EUR | 301.41% |
| 2012 | 27.47 Million EUR | -15.83% |
| 2011 | 32.63 Million EUR | -7.31% |
| 2010 | 35.21 Million EUR | 50.31% |
| 2009 | 23.42 Million EUR | 67.7% |
| 2008 | 13.96 Million EUR | 32.1% |
| 2007 | 10.57 Million EUR | 3.03% |
| 2006 | 10.26 Million EUR | 4.48% |
| 2005 | 9.82 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 313.6 Million EUR | -8.07% |
| 2024 Q2 | 300.29 Million EUR | -4.24% |
| 2023 Q2 | 351.86 Million EUR | -8.66% |
| 2023 Q3 | 363.01 Million EUR | 3.17% |
| 2023 FY | 341.14 Million EUR | -15.04% |
| 2023 Q1 | 385.21 Million EUR | -4.07% |
| 2023 Q4 | 341.14 Million EUR | -6.03% |
| 2022 Q3 | 533.1 Million EUR | -15.63% |
| 2022 FY | 401.54 Million EUR | -37.92% |
| 2022 Q1 | 629.3 Million EUR | -2.7% |
| 2022 Q2 | 631.85 Million EUR | 0.4% |
| 2022 Q4 | 401.54 Million EUR | -24.68% |
| 2021 Q2 | 668.03 Million EUR | 28.04% |
| 2021 FY | 646.77 Million EUR | 73.98% |
| 2021 Q4 | 646.77 Million EUR | 0.0% |
| 2021 Q1 | 521.75 Million EUR | 40.35% |
| 2020 FY | 371.74 Million EUR | 186.9% |
| 2020 Q1 | 143.41 Million EUR | 10.69% |
| 2020 Q2 | 278.29 Million EUR | 94.04% |
| 2020 Q3 | 373.45 Million EUR | 34.2% |
| 2020 Q4 | 371.74 Million EUR | -0.46% |
| 2019 Q3 | 119.02 Million EUR | 1.36% |
| 2019 FY | 129.57 Million EUR | 49.41% |
| 2019 Q2 | 117.41 Million EUR | 12.3% |
| 2019 Q1 | 104.55 Million EUR | 20.56% |
| 2019 Q4 | 129.57 Million EUR | 8.86% |
| 2018 Q4 | 86.72 Million EUR | 1.3% |
| 2018 Q2 | 89.53 Million EUR | -2.45% |
| 2018 Q1 | 91.78 Million EUR | -5.06% |
| 2018 FY | 86.72 Million EUR | -10.3% |
| 2018 Q3 | 85.61 Million EUR | -4.38% |
| 2017 Q2 | 100.05 Million EUR | 0.96% |
| 2017 Q4 | 96.67 Million EUR | 1.21% |
| 2017 Q3 | 95.52 Million EUR | -4.54% |
| 2017 FY | 96.67 Million EUR | -9.51% |
| 2017 Q1 | 99.1 Million EUR | -7.23% |
| 2016 FY | 106.83 Million EUR | -18.36% |
| 2016 Q2 | 105.51 Million EUR | -1.92% |
| 2016 Q4 | 106.83 Million EUR | 1.37% |
| 2016 Q3 | 105.38 Million EUR | -0.13% |
| 2016 Q1 | 107.58 Million EUR | -17.78% |
| 2015 FY | 130.85 Million EUR | 26.95% |
| 2015 Q1 | 132.19 Million EUR | 28.25% |
| 2015 Q2 | 132.11 Million EUR | -0.06% |
| 2015 Q3 | 129.1 Million EUR | -2.28% |
| 2015 Q4 | 130.85 Million EUR | 1.35% |
| 2014 FY | 103.07 Million EUR | -6.54% |
| 2014 Q1 | 104.07 Million EUR | -5.63% |
| 2014 Q2 | 102.47 Million EUR | -1.53% |
| 2014 Q4 | 103.07 Million EUR | -0.4% |
| 2014 Q3 | 103.48 Million EUR | 0.98% |
| 2013 FY | 110.28 Million EUR | 301.41% |
| 2013 Q4 | 110.28 Million EUR | 21.25% |
| 2013 Q3 | 90.94 Million EUR | -26.69% |
| 2013 Q2 | 124.06 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 Q2 | 27.22 Million EUR | 0.0% |
| 2012 Q4 | 27.47 Million EUR | 0.0% |
| 2012 FY | 27.47 Million EUR | -15.83% |
| 2011 FY | 32.63 Million EUR | -7.31% |
| 2011 Q2 | 37.62 Million EUR | 0.0% |
| 2011 Q4 | 32.63 Million EUR | 0.0% |
| 2010 Q2 | 38.03 Million EUR | 0.0% |
| 2010 FY | 35.21 Million EUR | 50.31% |
| 2010 Q4 | 35.21 Million EUR | 0.0% |
| 2009 FY | 23.42 Million EUR | 67.7% |
| 2009 Q4 | 23.42 Million EUR | 0.0% |
| 2008 FY | 13.96 Million EUR | 32.1% |
| 2007 FY | 10.57 Million EUR | 3.03% |
| 2006 FY | 10.26 Million EUR | 4.48% |
| 2005 FY | 9.82 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Boiron SA | 198.7 Million EUR | -71.687% |
| Laboratorios Farmaceuticos Rovi, S.A. | 256.39 Million EUR | -33.057% |
| Vetoquinol SA | 165.12 Million EUR | -106.601% |
| AB Science S.A. | 46.5 Million EUR | -633.517% |
| Nanobiotix S.A. | 95.74 Million EUR | -256.323% |
| PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -1227.667% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -7402.617% |
| BioSenic S.A. | 32.26 Million EUR | -957.352% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -160.312% |
| Formycon AG | 387.61 Million EUR | 11.988% |